Ask a doctor about a prescription for FORTACIN 150 mg/mL + 50 mg/mL CUTANEOUS SPRAY SOLUTION
Package Leaflet: Information for the User
Fortacin 150 mg/ml + 50 mg/ml solution for cutaneous spray
lidocaine/prilocaine
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Follow exactly the administration instructions of the medicine contained in this leaflet or as indicated by your doctor or pharmacist.
Contents of the Package Leaflet
Fortacin is a combination of two medicines: lidocaine and prilocaine. These belong to a group of medicines called local anesthetics.
Fortacin is indicated for the treatment of premature ejaculation from the first sexual intercourse, in adult men (over 18 years). This occurs when ejaculation always or almost always occurs within the first minute of sexual intercourse, causing a negative emotional impact. Fortacin works by reducing the sensitivity of the head of the penis to prolong the time until ejaculation.
Do not use Fortacin
Warnings and precautions
Consult your doctor or pharmacist before starting to use Fortacin
Premature ejaculation may be due to a disease that requires medical supervision. If this product used directly does not provide relief, consult a doctor.
Use with condoms
Avoid accidental contact:
Contact with other mucous membranes:
Possible transfer to the partner, e.g., to the vagina or anus:
In case the patient or their partner develop skin rashes or irritation, treatment with Fortacin should be discontinued. If symptoms persist, consult a doctor.
Children and adolescents
This medicine should not be administered to children or adolescents under 18 years of age.
Other medicines and Fortacin
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. It is especially important that you inform a doctor before using Fortacin if you are taking any of the following medicines that may interact with Fortacin:
The risk of methemoglobinemia may also increase due to the use of certain dyes (aniline dyes) or the pesticide naphthalene, so you should inform your doctor if you work with dyes or chemical pesticides.
Pregnancy, breastfeeding, and fertility
Fortacin is not authorized for use in women.
Ask your doctor or pharmacist for advice before taking any medicine.
Pregnancy
Fortacin should not be used while your partner is pregnant unless you use an effective male condom, as indicated earlier in section 2 "Use with condoms", to avoid fetal exposure.
Breastfeeding
This medicine can be used while your partner is breastfeeding.
Fertility
Fortacin may reduce the possibility of pregnancy. Therefore, patients who wish to conceive should avoid using Fortacin, or if the medicine is essential to achieve penetration, they should wash the glans of the penis as thoroughly as possible five minutes after applying Fortacin but before sexual intercourse.
Follow exactly the administration instructions of this medicine contained in this leaflet. In case of doubt, ask your doctor or pharmacist.
The recommended dose of Fortacin is 3 sprays (3 sprays = 1 dose) on the head of the penis at least 5 minutes before sexual intercourse. A maximum of 3 doses can be administered within 24 hours with an interval of at least 4 hours between doses.
Do not exceed the maximum recommended dose (3 doses in 24 hours).
Instructions for use
If you use more Fortacin than you should
If you apply too much, wipe it off.
The following symptoms may occur when too much Fortacin is used. Contact your doctor or pharmacist if you experience any of them. It is very unlikely to happen if used according to the instructions:
In severe cases of overdose, symptoms may include seizures, hypotension, slowed breathing, respiratory arrest, and cardiac arrhythmia. The effects can be potentially fatal.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects have been reported with Fortacin in male patients:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
The following side effects have been reported with Fortacin in sexual partners:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Reporting of side effects
If you experience any side effects, consult your doctor or pharmacist, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label of the spray container and on the carton after "EXP". The expiry date is the last day of the month stated.
Store below 25 °C. Do not freeze. The container should be discarded 12 weeks after the first use.
The metal container is pressurized. Do not pierce, break, or burn, even if it appears to be empty. A residual volume of unusable fluid will remain in the container after all doses have been administered.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Fortacin
Appearance of Fortacin and container contents
Fortacin is a colorless or light yellow solution for cutaneous spray, in an aluminum spray container with a dosing valve.
Each box contains 1 spray container with 6.5 ml or 5 ml of solution.
Marketing authorization holder
Recordati Ireland Ltd.
Raheens East
Ringaskiddy Co. Cork
Ireland
Manufacturer
Pharmaserve (North West) Ltd
9 Arkwright Road
Astmoor Industrial Estate
Runcorn WA7 1NU
United Kingdom
Recordati Industria Chimica e Farmaceutica S.p.A.
Via Matteo Civitali 1
20148 Milano
Italy
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
BelgiumLithuania
Recordati Ireland Ltd. Recordati Ireland Ltd.
Tel: + 353 21 4379400 Tel: + 353 21 4379400
GreeceLuxembourg
Recordati Ireland Ltd. Recordati Ireland Ltd.
Tel: + 353 21 4379400 Tel: + 353 21 4379400
Czech RepublicHungary
Herbacos Recordati s.r.o. Recordati Ireland Ltd.
Tel: + 420 466 741 915 Tel: + 353 21 4379400
DenmarkMalta
Recordati Ireland Ltd. Recordati Ireland Ltd.
Tel: + 353 21 4379400 Tel: + 353 21 4379400
GermanyNetherlands
Recordati Pharma GmbH Recordati Ireland Ltd.
Tel: + 49 (0) 731 7047 0 Tel: + 353 21 4379400
EstoniaNorway
Recordati Ireland Ltd. Recordati Ireland Ltd.
Tel: + 353 21 4379400 Tel: + 353 21 4379400
GreeceAustria
Recordati Hellas Pharmaceuticals A.E. Recordati Ireland Ltd.
Tel: + 30 210-6773822 Tel: + 353 21 4379400
SpainPoland
Casen Recordati, S.L. RECORDATI POLSKA sp. z o.o.
Tel: + 34 91 659 15 50 Tel: + 48 22 206 84 50
FrancePortugal
Laboratoires BOUCHARA-RECORDATI Jaba Recordati, S.A.
Tel: + 33 1 45 19 10 00 Tel: + 351 21 432 95 00
CroatiaRomania
Recordati Ireland Ltd. Recordati România S.R.L.
Tel: + 353 21 4379400 Tel: + 40 21 667 17 41
IrelandSlovenia
Recordati Ireland Ltd. Recordati Ireland Ltd.
Tel: + 353 21 4379400 Tel: + 353 21 4379400
IcelandSlovakia
Recordati Ireland Ltd. Herbacos Recordati s.r.o.
Tel: + 353 21 4379400 Tel: + 420 466 741 915
ItalyFinland
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Ireland Ltd.
Tel: + 39 02 487871 Tel: + 353 21 4379400
CyprusSweden
Recordati Ireland Ltd. Recordati Ireland Ltd.
Tel: + 353 21 4379400 Tel: + 353 21 4379400
LatviaUnited Kingdom
Recordati Ireland Ltd. Recordati Pharmaceuticals Ltd.
Tel: + 353 21 4379400 Tel: + 44 (0) 1491 576 336
Date of the last revision of this leaflet:{MM/AAAA} Other sources of information
Detailed and updated information about this medication is available by scanning the QR code below and on the packaging with a smartphone.
This same information is available at the following URL: www.fortacin.eu QR code www.fortacin.eu
Detailed information about this medication is available on the website of the European Medicines Agency: http://www.ema.europa.eu.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for FORTACIN 150 mg/mL + 50 mg/mL CUTANEOUS SPRAY SOLUTION – subject to medical assessment and local rules.